Venture Capital

The parent company of Hometown Hero CBD is launching Black Sheep Kratom, betting on quality and transparency in a booming but unregulated wellness category.

The meal kit giant partners with the celebrity chef for an Italian-inspired menu, a strategic move to capture a larger slice of the competitive market.

Soar Autism Center launches a free, 40-hour RBT course focused on the play-based ESDM model, tackling workforce shortages and raising care standards.

The architect of Tesla's dry electrode acquisition is back, betting on AM Batteries' DBE 2.0 to revolutionize how batteries are made. Here's why.

A new public-private partnership in Sweden aims to revolutionize EV batteries with high-density, sustainable graphite-silicon anodes.

With a new financial architect at the helm, HydroGraph aims to turn its breakthrough graphene technology into global commercial success.

As Flex heads to a key investor conference, a look at its record financials and pivotal role in building the high-stakes infrastructure for the AI era.

BioNexus Gene Lab appoints Matthew Barsing to lead its Chemrex subsidiary, signaling a strategic overhaul from industrial chemicals to biotech and advanced tech.

A new summit reveals the high-stakes, collaborative effort to build the open standards that will move AI agents from futuristic demos to enterprise reality.

Recursion, HighRes, and NVIDIA are pioneering automated drug discovery. Inside the 'Physical AI' revolution poised to radically accelerate the hunt for new cures.

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

With a $2.5B valuation and new brand, Mews is betting its unified platform can solve hospitality's biggest problems: fragmentation and inefficiency.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

With a new CEO known for commercial turnarounds, oneworld signals a strategic push for tech integration, customer value, and competitive growth.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?